Glytr Therapeutics, Inc.
Publicly observedSan Carlos, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Carlos | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Glytr Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | ZKQLT6S8LXY9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant10 Sept 2025Publicly observed
NIH SBIR/STTR award: Maximizing GlyTR pan-cancer immunotherapy by enhancing target density
USD 1,002,331.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant10 Sept 2025Publicly observed
NIH SBIR/STTR award: Maximizing GlyTR pan-cancer immunotherapy by enhancing target density
USD 463,510.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant21 Sept 2023Publicly observed
NIH SBIR/STTR award: Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
USD 1,085,460.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.